Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on oncology, announced its participation in the Cantor Fitzgerald Future of Oncology Symposium scheduled for April 3-5, 2023. The company will present on April 4 at 8:15 AM ET. Compass Therapeutics is developing proprietary antibody-based therapeutics targeting various human diseases, emphasizing the interplay between angiogenesis, the immune system, and tumor growth. Their innovative pipeline aims to address critical biological pathways for effective anti-tumor responses, advancing both standalone therapies and combination strategies. Founded in 2014, the company is headquartered in Boston, Massachusetts.
Details
News Market Reaction – CMPX
The recorded move for CMPX in the trading session of this news was +0.32%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Cantor Fitzgerald Future of Oncology Symposium, which is taking place virtually on April 3 – 5, 2023.
Presentation details:
Date: Tuesday, April 4
Time: 8:15 AM ET
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass’s pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. Compass was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics, Inc. website at www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Communications Manager
media@compasstherapeutics.com
617-500-8099
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.